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Abstract
Background: Randomised control trials are regarded as the gold standard for evaluating the effectiveness and
efficacy of healthcare interventions with thousands of trials published every year. Despite significant investment in
infrastructure, a staggering number of clinical trials continue to face challenges with retention. Dropouts could lead
to negative consequences—from lengthy delays to missing data that can undermine the results and integrity of
the trial.
Summarising evidence from non-randomised evaluations of retention strategies could provide complementary
information to randomised evaluations that could guide trialists to the most effective ways of increasing
retention of participants in clinical trials.
Methods: The following electronic databases will be searched for relevant studies: EMBASE, MEDLINE, the
Cochrane Controlled Trials Register, and Cochrane Methodology Register and the search will be limited to
English-published studies during the last 10 years to increase relevance to current trials. Non-randomised
studies (observational studies) including a comparison of two or more strategies to increase participant
retention in randomised trials or comparing one or more strategies with no strategy will be included. The
primary outcome will be the proportion of participants remained at the primary analysis as determined in
each retention study.
Discussion: This review aims to gather and evaluate evidence on the effect of retention strategies examined
in non-randomised studies. It is imperative to collect evidence from obseravational studies to infer whether or
not these studies could be considered a practical way to complement or even replace a broadly favourable
randomised design. If we find that non-randomised studies to be included in this review are of high quality
with adequate control of biases, we will recommend to trialists and others not to rely exclusively on randomised
studies and to give meticulous attention to the plentiful evidence that can be obtained from non-randomised studies.
Should the results of this review suggest that evaluating retention strategies in observational studies provides
insufficient evidence to trialists planning their retention strategies, we will be able to say that there is little
point in conducting non-randomised studies and that they would do better to invest their time and resources
in a randomised evaluation if possible. Where a non-randomised study design is chosen, the review authors
will offer recommendations to trialists and others regarding how to ensure that these studies are conducted in
a way that can minimise the risk of bias and increase confidence in the findings.
Systematic review registration: PROSPERO 2017:CRD42017072775.
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Background
Retention of participants is essential to ensure the
statistical power and internal validity of clinical trials.
High attrition rates reduce power and can bias the esti-
mates of intervention effect, especially if participants lost
to follow-up are different from those retained at follow
up or if differential attrition is evident between the
intervention and control groups in a randomised trial
[1]. In a review which evaluated missing outcome data
in randomised trials published in four major journals, it
was found that 89% of studies reported some missing
data and 18% of studies had more than 20% of
participants with partly missing outcome data [2].
Recent work with a 2004–2016 cohort of trials funded
by the UK Health Technology Assessment Programme
reported the median proportion of randomised partici-
pants retained to be 89%, meaning that 50% of trials did
not have primary outcome data for more than 11% of
participants [3].
It is generally accepted that a trial with under 5% loss
to follow-up will have a little bias, while missing out-
come data from more than 20% may pose a major threat
to the validity of the study [4]. Some trial results, how-
ever, can be far more vulnerable to missing data than
this suggests. The Fragility Index, a way of assessing how
fragile a trial conclusion developed by Michael Walsh
and colleagues [4] often shows that what is considered
statistically significant at P < 0.05 can be turned insignifi-
cant by a handful of events going in the opposite direc-
tion. Crucially, these authors found that for 53% of
trials, the number of event swaps needed to change the
conclusion was less than the number lost to follow-up.
While modest missing data can be handled with statis-
tical methods, the risk of bias can remain [5] and it is
impossible to meaningfully fix substantial missing data
by statistical means [6].
Attrition is therefore an important and often under-
estimated concern for randomised trials, and it is
imperative that trialists plan to achieve as close to
complete follow-up as possible. Evaluations to explore
effective retention strategies have increased recently but
still comes a distant second to recruitment in terms of
the volume of studies [7]. Different retention strategy
themes were identified in three systematic reviews: 1)
contact and scheduling methods, 2) characteristics of
follow-up visits, 3) non-monetary incentives, 4) monet-
ary incentives, 5) reminders to non-respondents, 6)
intensive tracking efforts, 7) description of the study, 8)
study benefits, 9) reimbursement and 10) involvement of
the community [7–9]. Notwithstanding the knowledge
acquired from these reviews, an important limitation is
that they did not provide a detailed exploration of reten-
tion strategies and potentially disregarded other strat-
egies or themes that may have been evaluated using
non-randomised designs. They also did not give much
attention to the pre-trial stage, where the likelihood
of identifying and addressing future problems is greatest.
The potential contribution that randomised and non-
randomised studies can make to the evaluation of effect-
iveness has provoked considerable controversy [10]. A
randomised controlled trial (RCT) is considered as the
gold standard design for the assessment of the effective-
ness and efficacy of healthcare interventions [11]. Never-
theless, some do not consider RCTs to be the most
suitable design to evaluate complex and context-
dependent interventions [12, 13]. Several scenarios
remain where an RCT may be inappropriate, unneces-
sary, or impossible [14]. Non-randomised studies, such
as controlled and uncontrolled before-after studies, are
often undertaken to obtain evidence on the effectiveness
of interventions that cannot be randomised, or which
are highly unlikely to be tested in randomised studies or
where randomisation was simply not considered for one
reason or another. In certain circumstances, randomisa-
tion may be misleading where the random allocation
process may have an influence on the effectiveness of
the intervention. Furthermore, experimentation may be
practically impossible as investigators may not agree that
important uncertainty exists about the relative effective-
ness of different interventions and thus regard the study
to be unnecessary or unethical.
The rationale behind conducting this review
Including non-randomised effect evaluations in system-
atic reviews could be viewed as problematic, particularly
when appraising study quality and the likelihood of
selection bias and its impact on study results [15]. How-
ever, a recent Cochrane review of reviews has shown
that there is insufficient evidence of significant effect
estimate differences between RCTs and observational
studies (79% of the included reviews showed no signifi-
cant differences between observational studies and
RCTs) [16]. Evidence from this Cochrane review sug-
gests that observational studies can be conducted with
sufficient rigour to provide complementary evidence or
replicate the results of randomised trials. Moreover, we
think that the systematic evaluation of what is expected
to be a considerable amount of research is crucial
(chiefly because without collecting and critically analys-
ing these studies, they are currently disregarded), worth-
while (as there might be significant unknown effects),
and will provide tangible results for the trials stake-
holders regardless of whether the outcomes support one
or more interventions.
To our knowledge, this is the first systematic review
that aims to synthesise evidence from non-randomised
evaluations of retention strategies in order to supple-
ment existing randomised trial evidence, which together
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can contribute to optimising rates of retention success
in RCTs. It is possible that our review might find that
non-randomised retention strategy evaluation has little
benefit, in this case, review authors will offer guidance
to trialists and others to ensure that these studies are
conducted in a way that can be considered comparable
to a well-designed randomised study.
Objectives
 To provide a comprehensive review of retention
strategies examined through non-randomised study
designs.
 To measure the effect of strategies to promote
retention on the number of participants retained in
randomised trials and to explore whether the effect
varied by trial setting, trial strategy, and retention
behaviour (non-return of questionnaires, non-
attendance at follow up visits and active withdrawal
(i.e. through participant request of no further follow
up) from the trial).
Methods
The systematic review protocol was developed according
to the Preferred Reporting Items for Systematic review
and Meta-Analysis Protocol (PRISMA-P) guidelines
statement, and the PRISMA-P checklist is endorsed
(Additional file 1). This protocol will be made publicly
available.
Inclusion criteria
Studies to be included
Non-randomised studies comparing two or more strat-
egies to increase participant retention in randomised tri-
als or comparing one or more strategies with no
strategy. Non-randomised or observational studies are
defined as any quantitative study testing the effectiveness
of retention strategies where participants have been allo-
cated to the intervention and control groups by a
method that is not random. Eligible non-randomised
study designs include observational studies, cohort stud-
ies, before-and-after studies, case-control studies, histor-
ically controlled studies, uncontrolled longitudinal
studies, interrupted time series, and uncontrolled
before-and-after studies. The retention trials should be
nested in real “host” trials (including feasibility studies)
but not hypothetical trials.
Participants
Participants from any gender, age, language, cultural,
and geographic group will be considered. Studies in
healthcare (including different disease areas and all disci-
plines) and non-healthcare (social sciences, education)
topics will be included.
Types of interventions
Any strategy designed to optimise retention directed
towards the participant, clinician, or researcher will be
considered. Trials that include a combination of strat-
egies to improve retention will also be included. The
following strategies could be included:
 Strategies that motivate participants or clinicians
(e.g. gifts or monetary incentives) with a primary
focus on collection of outcome data;
 Strategies that aim to facilitate communication with
participants (e.g. telephone follow-up);
 Methodology strategies (e.g. different questionnaire
formats or variations in the frequency of follow-up
visits);
 Multifaceted strategies (e.g. intensive tracing efforts
to locate study participants).
 Strategies that maximise rapport with study
participants (e.g. behavioural and motivational
strategies).
 Relevance of outcome selection (e.g. disease specific
vs generic)
Outcome measures
Primary outcomes The primary outcome will be the
number of participants retained at the primary analysis
point as stated in each retention study. In cases where
the time points to measure the primary outcome are not
predetermined, the first time point reported will be con-
sidered. Where retention at different time points is
stated and no definite time point for the primary out-
come for the retention study is reported, the closest time
point to the intervention in the retention study analyses
will be considered.
Secondary outcomes Retention at secondary analysis
points and cost of retention strategy per participant.
Exclusion criteria
 Studies published before 2007
 Studies where retention strategies are not the
primary focus.
 Studies that do not provide retention outcomes.
 Studies that only examine predictors of loss to
follow-up.
Search strategy The search strategy was constructed in
discussion with an information specialist (CF) with ex-
pertise in healthcare databases and systematic reviews.
EMBASE, MEDLINE, the Cochrane Controlled Trials
Register, and Cochrane Methodology Register will be
searched. The search will be limited to English-
published studies during the last 10 years to increase
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relevance to current trials. The search strategy contains
both medical subject heading (MeSH) and non-MeSH
terms. The search strategy combines text and vocabulary
words for concepts such as “retention”, “attrition”, “loss
to follow-up”, and “participant dropouts”.
Other search methods will include hand-searching of
reference lists of systematic reviews of randomised re-
tention strategies to identify studies that were excluded
on account of being not randomised. All retrieved cita-
tions will be screened by two independent reviewers to
determine eligibility.
The following multifile search strategy for MEDLINE
and EMBASE (OVID) will be adapted for the other data-
bases listed.
1 (attrition adj2 (minimi$ or prevent$ or lessen$ or
decreas$ or reduc$)).tw.
2 (drop$-out$ adj2 (minimi$ or prevent$ or lessen$ or
decreas$ or reduc$)).tw.
3 (dropout$ adj2 (minimi$ or prevent$ or lessen$ or
decreas$ or reduc$)).tw.
4 (strateg$ adj2 (dropout$ or drop$-out$)).tw.
5 ((lost or loss) adj2 (follow-up or followup)).tw.
6 (withdrawl$ adj2 (minimi$ or prevent$ or lessen$ or
decreas$ or reduc$)).tw.
7 (strateg$ adj2 (attrition or followup or follow-
up)).tw.
8 (retention adj5 (increas$ or encourag$ or maximi$
or promot$ or improv$ or influenc$ or
success$)).tw.
9 (compliance adj2 (increas$ or encourag$ or maximi$
or promot$ or improv$)).tw.
10 (strateg$ adj2 response$).tw.
11 (questionnaire$ adj3 respon?e$ adj2 (strateg$ or
increas$ or encourag$ or maximi$ or promot$ or
improv$)).tw.
12 (retention adj1 rate$).tw.
13 (attrition adj1 rate$).tw.
14 (follow up adj1 rate$).tw.
15 (retention adj3 (strateg$ or intervention? or
method$ or technique$)).tw.
16 (compliance adj3 (strateg$ or intervention? or
method$ or technique$)).tw.
17 (questionnaire$ adj3 response$ adj2 (method$ or
technique$)).tw.
18 ((incentive$ or reminder$ or method$) adj3
(Retention or respon?e$)).tw.
19 (difficult$ adj2 (retain$ or retention)).tw.
20 (retention adj3 (participant? or subject? or
patient?)).tw.
21 ((increase or maintain$) adj3 (partipa$ or respon?e$
or compliance)).tw.
22 Patient Dropouts/use ppez
23 Patient Dropout/use emef
24 or/1–23
25 research subjects/use ppez
26 research subject/use emef
27 exp. Clinical Trials as Topic/use ppez
28 exp. “clinical trial (topic)”/use emef
29 Observational Study as Topic/
30 ((research or trial? or study or studies or pilot or
program$ or longitudinal or prospective or
retrospective) and (attrition or drop$ out$ or
dropouts or withdrawl$ or follow up or retention or
retain$ or compliance or participation or recruit$ or
engag$)).ti.
31 or/25–30
32 24 and 31
33 (letter or editorial or comment or note or
abstract).pt.
34 32 not 33
35 limit 34 to english language
36 limit 35 to yr. = “2010–2017” [Embase 3890
MEDLINE 3085]
37 limit 36 to yr. = “2010–2014”
38 remove duplicates from 37
39 limit 36 to yr. = “2015–2017”
40 remove duplicates from 39
41 38 or 40
Data management The EndNote reference management
software will be used to manage the search results, and
the EndNote de-duplication tool will be applied to
remove any duplicate records. An Excel spreadsheet will
be used to track all inclusions/exclusions that will help
us to develop a Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flow diagram
when the screening process is carried out.
Identification of eligible studies The abstracts of all
records retrieved from the search will be screened by
two independent reviewers. The full-text check will be
carried out for all potentially eligible studies by two
independent review authors. Where necessary, study
authors will be contacted to seek information that will
resolve any questions regarding the eligibility of studies.
Any disagreements among review authors will be
discussed and resolved. Where necessary, a third
reviewer will be involved to adjudicate unresolved
disagreements.
Data extraction Two reviewers will independently
extract information from each of the included studies
using a standardised data extraction form designed for
the purpose of the review. Data to be extracted for the
host trial will be objective, trial setting, clinical area, and
comparators. For the nested retention study, data for
start time relative to the host trial, number of
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participants, objective, primary outcome, and method of
follow-up will be extracted. Details of the retention
intervention will include type, timing and frequency of
administration, method of allocation, numbers allocated
to groups and retained at primary analysis, and data
necessary to assess the risk of bias. Retention strategies
and retention rates at different follow-up time points
will be extracted independently. Any disagreement will
be discussed and resolved. Where necessary, a third
reviewer will be involved to adjudicate unresolved dis-
agreements. Where required, corresponding authors will
be contacted to seek additional information.
Quality assessment of included studies The Cochrane
ROBINS-I (“Risk Of Bias In Non-randomised Studies -
of Interventions”) [17] tool will be used to appraise the
quality of included studies. The tool offers a structured
and comprehensive approach for the assessment of non-
randomised studies of interventions. Central features of
ROBINS-I include the use of signalling questions to
guide risk of bias judgements within seven bias domains.
The quality assessment will be carried out by two review
authors. Any disagreement will be discussed and
resolved. Where necessary, a third reviewer will be
involved to adjudicate unresolved disagreements. Where
necessary, study authors will be contacted for additional
information to clarify study methods.
Assessment of heterogeneity Where study population,
intervention, and outcome data are adequately similar to
justify pooling the results in a meta-analysis, visual evi-
dence of heterogeneity in forest plots will be investigated
together with statistical evidence of heterogeneity using
the chi-square statistic, and the I2 test will be used to
quantify the degree of heterogeneity [18]. Where signifi-
cant heterogeneity is found (I2 ≥ 50%), informal explana-
tions will be conducted and the random-effect model
will be used to summarise data where appropriate.
Data analysis and synthesis If the included studies are
statistically homogeneous (I2 < 50%), a meta-analysis
using a fixed-effect model will be performed. Otherwise,
the random-effect model will be employed. The causes
of heterogeneity will be evaluated to supplement choice
of the model using the Cochrane Handbook for System-
atic Reviews of Interventions Version 5.1.0 [19].
It is anticipated that there will be much diversity in
the included studies. Where it is not appropriate to
perform a meta-analysis, included studies will be com-
bined in a narrative synthesis. To ensure the synthesis is
a rigorous and transparent process, review authors will
meet to discuss and categorise different retention strat-
egies from the included studies. Firstly, reviewers will
review the strategies independently and assign each
retention strategy to the relevant category. The inde-
pendent results will then be discussed and differences
will be reconciled before a final list of major retention
categories is provided.
Measures of the effect For dichotomous outcomes
(retention or attrition rates), risk ratios and their 95%
confidence intervals will be calculated to determine the
effect of strategies on participant retention. It is not
clear how participant benefits or difficulties with strat-
egies will be measured, so the data available will be
examined and then the most appropriate effect measure
will be determined.
Unit of analysis issues It is anticipated that most of the
included studies will be before-and-after studies with the
individual participant as the unit of analysis. We will
only include clustered studies in the meta-analysis if suf-
ficient data were reported to allow inclusion of analyses
that adjusted for clustering; an odds ratio (OR) will be
used in the summary effect of the meta-analysis result if
the risk difference or risk ratio clustering adjusted ana-
lyses were not possible with available data.
Handling missing data The amount and reasons for
missing data will be recorded. Every effort will be made
to contact study authors for data essential to appraise
the quality of included studies, numbers allocated to
each group, and number of participants retained at the
primary endpoint. When assessing the risk of bias, drop-
outs will be reported and considered as a potential
source.
Assessment of reporting bias Where sufficient data
will be available (10 or more studies of the same reten-
tion strategy, study population, and outcomes), tests for
funnel plot asymmetry will be used to investigate report-
ing bias.
Assessment of the quality of evidence The Grading of
Recommendations Assessment Development and Evalu-
ation (GRADE) system will be used to rate the certainty
of evidence from the included studies [20]. Evidence
from robust non-randomised studies will be generally
graded as low quality. Nevertheless, if the effect yielded
by such studies is large enough and there is no clear evi-
dence of bias to explain those effects, the evidence might
be rated as moderate or even high quality. GRADE
assessments will be applied independently by two
reviewers to judge the certainty of the evidence.
Discussion
This review will gather and evaluate evidence on the
effect of retention strategies examined in non-
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randomised studies. It is clear that many researchers are
somewhat dichotomised concerning whether to rely
solely on randmoised study designs while searching for
evidence on effective retention strategies or to also con-
sider non-randomised studies as a reliable surrogate to
randomised studies when conducted with sufficient
rigour. Recent evidence suggests that high-quality non-
randomised studies can provide outcomes that are simi-
lar to those found in randomised studies and that study
quality may have a greater impact on treatment effect
size than randmisation alone, denoting that randmisa-
tion should not be considered as a sound proxy for over-
all trial quality [16]. Therefore, it is imperative to collect
evidence from observational studies to infer whether or
not these contentious studies could be considered a
practical way to complement or even replace a rando-
mised design in some cases. If we find that non-
randomised studies to be included in this review are of
high quality with adequate control of biases, we will rec-
ommend to trialists and others not to rely exclusively on
randomised studies and to direct their attention to the
plentiful evidence that can be generated from non-
randomised evaluations. If the included studies are of
low quality with inappropriate control of confounding
factors that might threaten the validity of findings,
review authors will be able to recommend to funders
and trial stakeholders that researchers should only con-
sider conducting observational studies of high methodo-
logical quality that provide results that can be part of an
evidence base to inform trial design decisions. Further-
more, the review might introduce innovative and prom-
ising retention strategies that need to be tested in a
more rigorous randomised study.
Additional file
Additional file 1: There are no additional titles or legends to be
included in this systematic review protocol. The PRISMA checklist is
endorsed and has been uploaded as a table file. (DOCX 18 kb)
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